BRCA1/2 status and chemotherapy response score to tailor ovarian cancer surgery.

Riccardo Ponzone

Critical reviews in oncology/hematology 2021 Jan

filter terms:

In advanced ovarian cancer (AOC) the complete eradication of all macroscopic disease at primary debulking surgery (PDS) is associated with the best outcome. If this cannot be achieved, neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) can make complete cytoreduction possible while reducing postoperative morbidity. It is still debated if PDS and NACT- IDS are associated with similar survival and if they provide different outcomes when optimal cytoreduction is achieved. For a tailored surgical planning, accurate prediction of tumor's resectability, assessment of patient's performance status and in-depth knowledge of tumor biology are required. Both BRCA1/2 status and the "chemotherapy response score" are reliable markers of chemosensitivity and may thus improve our way to triage patients to PDS or NACT-IDS; furthermore, they could be used to modulate our surgical approach and define appropriate subgroups of patients for whom new therapies should be tested. Copyright © 2020 Elsevier B.V. All rights reserved.

Citation

Riccardo Ponzone. BRCA1/2 status and chemotherapy response score to tailor ovarian cancer surgery. Critical reviews in oncology/hematology. 2021 Jan;157:103128